Disc Medicine IRON Increase Decrease In Accrued External Research And Development Expenses
Increase Decrease In Accrued External Research And Development Expenses at other companies
Other financials
Where this comes from
Reported directly by Disc Medicine in its filing.
Tagged under the XBRL concept iron:IncreaseDecreaseInAccruedExternalResearchAndDevelopmentExpenses.
The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Disc Medicine's increase decrease in accrued external research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Disc Medicine's increase decrease in accrued external research and development expenses?
- Disc Medicine (IRON) reported increase decrease in accrued external research and development expenses of $686K in Q1 2026.
- How has Disc Medicine's increase decrease in accrued external research and development expenses changed year-over-year?
- Disc Medicine's increase decrease in accrued external research and development expenses increased by 145.0% year-over-year, from $280K to $686K.
- What does increase decrease in accrued external research and development expenses mean?
- This reflects the change in liabilities related to research and development services performed by third parties but not yet paid for by the company. An increase indicates that the company has incurred R&D expenses that will require future cash outflows, while a decrease indicates the settlement of these obligations. It is a key indicator of the timing of R&D spending and vendor payment cycles.